GLP-1 (glucagon-like peptide 1) and its mimetic exendin-4 are used against Type 2 diabetes. C-peptide has also proven promising to enhance insulin action. Since insulin secretion in vivo can be rapidly tuned by changes in islet microcirculation, we evaluated the influence of GLP-1, exendin-4 and C-peptide on pancreatic IBF (islet blood flow), and dynamic changes in insulin secretion and glycaemia in the rat. Adult male Wistar rats were divided into four groups given intravenous saline, GLP-1, exendin-4 or C-peptide respectively and administered either saline or 30 % glucose. Furthermore, we investigated the effect of intravenous infusion of different doses of exendin-4 into either the femoral vein or the portal vein on islet microcirculation. A nonradioactive microsphere technique was adopted to measure the regional blood flow. Both GLP-1 and exendin-4 prevented the glucose-induced PBF (pancreatic blood flow) redistribution into the islets. Infusion of exendin-4 into the portal vein did not alter pancreatic islet microcirculation, while infusion of exendin-4 into femoral vein significantly decreased basal IBF. C-peptide increased basal IBF and the proportion of IBF out of total PBF, but did not affect the islet microcirculation after glucose administration. GLP-1, exendin-4 and C-peptide stimulated insulin secretion and significantly decreased glycaemia. Blocking NO formation did not prevent the decreased IBF and post-load glycaemia evoked by exendin-4, but further decreased IBF and KBF (kidney blood flow) and increased basal glycaemia. Blocking the vagus nerve enhanced pancreatic IBF and further decreased post-load glycaemia and KBF and increased basal glycaemia. The vascular modulatory effect on pancreatic islet microcirculation described herein, with subsequent effects on in vivo insulin secretion and glycaemia, might be one of the mechanisms underlying the anti-diabetic actions of GLP-1 and its long acting mimetic exendin-4, as well as that of C-peptide.
INTRODUCTION
Pancreatic islet β-cell dysfunction is now considered to be a requirement for, as well as an early lesion in, the development of both Type 1 and Type 2 diabetes [1] . To maintain normal islet endocrine function not only intracellular formation and release of insulin are mandatory but also the presence of an intact islet vascular system is crucial [2] . Changes in pancreatic islet microcirculation may impede insulin output in diabetic subjects, and could contribute to the pathogenesis of the disease. Islet hyperperfusion and abnormal modulation of IBF (islet blood flow) after glucose challenge have been observed in various animal models of glucose intolerance and diabetes, including obese animals [3] as well as the non-obese GK (Goto-Kakizaki) rats [4] .
GLP-1 [glucagon-like peptide 1; GLP-1-(7-36)] and its mimetics are promising antidiabetic agents, the effectiveness of which was confirmed by observations in clinical trials [5] [6] [7] [8] . Results from both in vitro [9] and in vivo [10] studies demonstrated a vasorelaxant effect of GLP-1-(7-36) in the pulmonary circulation and conduit arteries in rodents. Furthermore, GLP-1-(7-36) has been shown to prevent the increase of IBF induced by glucose administration in Wistar rats, and to decrease the elevated basal IBF in diabetic GK rats [4] . However, the rapid degradation of GLP-1-(7-36) largely limits its clinical use. Exendin-4 is a long-acting GLP-1 receptor agonist, possessing vasoactive effects that might be different from those of native GLP-1. Gardiner et al. [11] reported that exendin-4 decreased mesenteric blood flow in both a GLP-1 receptor-dependent and -independent way. In Type 2 diabetic rodent models, GLP-1 normalized the altered vascular tone, whereas exendin-4 did not affect the vascular responsiveness of the aorta [12] . Whether exendin-4 has the same vasoactive effect on islet microcirculation as GLP-1-(7-36) is unknown.
C-peptide has been reported to decrease glomerular hyperfiltration and increase nutritive endoneurial blood flow in Type 1 diabetic animal models [13] , and to increase forearm blood flow in Type 1 diabetic patients [14] , indicating that C-peptide might be a vasoactive peptide. If so, a more widespread action of C-peptide on the vasculature in other organs, including the abundantly vascularized endocrine pancreas, might exist. To our knowledge, one recently published in vitro study demonstrated that mouse C-peptide induced constriction of pancreatic islet arterioles of diabetic mice but had no effect on normoglycaemic controls [15] . Furthermore, there is one previous in vivo study when C-peptide doses in the picomolar range failed to affect splanchnic blood flow [16] . However, the effect of more physiological doses of C-peptide on islet perfusion has not been evaluated.
In view of the above, the present study aims to clarify the effects of the three peptides described, all with known effects on islet endocrine function, on dynamic changes of islet microcirculation, as well as changes of in vivo insulin secretion and glycaemia in rat.
MATERIALS AND METHODS

Animals
Male 3-month-old Wistar rats, weighing 350-420 g, were purchased from ScanBur. All animals were kept under standard conditions with controlled temperature and a 12 h light/12 h dark cycle and free access to tap water and pelleted food (Type R34; ScanBur). The study was approved by the local animal ethics committee of the Karolinska Institute, conforming to the 'Guide for the Care and Use of Laboratory Animals' published by U.S. National Institutes of Health (NIH publication No. 85-23, revised 1985) .
IPGTT (intraperitoneal glucose tolerance test)
A total of 21 rats were fully anaesthetized before and during the whole procedure. Right after the intraperitoneal injection of 30 % (w/v) d-glucose solution [2 g of glucose/kg of bw (body weight)], GLP-1 (50 μg/kg of bw; Sigma), exendin-4 (5 μg/kg of bw, provided by Amylin) and C-peptide (75 nmol/kg of bw, provided by Creative Peptides) were given as intravenous bolus injections. All substances were dissolved in 1 ml of saline. Control animals were injected with 1 ml of saline alone. Blood samples were drawn from the tail vein immediately before and 10, 30, 60 and 120 min after glucose administration. The area under the curve for the IPGTT was determined by computerized image analysis as described previously [17] .
Surgical procedure
Non-fasted rats were kept fully anaesthetized with an intraperitoneal injection of sodium thiobutabarbital (120 mg/kg of bw; Inactin, Research Biochemicals International), tracheotomized and placed on a heated operating table to keep the body temperature at 37
• C. Polyethylene catheters were inserted via the right carotid artery into the ascending aorta, and into the femoral artery [18] . Throughout the rest of the experiment, arterial blood pressure was monitored by a pressure transducer (PDCR 75/1; Druck) via the catheter placed in the carotid artery. The external jugular vein was then exposed for intravenous injection of tested substances. After the procedures were done, it took approximately 15-20 min until blood pressure became stable.
Administration of peptides and glucose
Rats were assigned into groups and administered intravenous bolus injection into the right jugular vein of 0.2 ml of saline, GLP-1 (50 μg/kg of bw), exendin-4 (5 μg/kg of bw) or C-peptide (75 nmol/kg of bw) respectively. The tested substances were dissolved in 0.2 ml of saline (0.9 %, w/v). Then 5 min after the injection, another intravenous injection of 1 ml of saline or 30 % (w/v) glucose was given into the same vein. These animals will be referred to below as saline-treated or glucose-treated. After another 5 min (10 min after the first injection), blood flow of the pancreas and islets was measured.
Administration of exendin-4 via different routes
As the portal vein wall reportedly contains a GLP-1-regulated glucose sensor [19] , we wanted to explore whether the GLP-1R (GLP-1 receptor) agonist exendin-4 had any effects in this system. The portal vein was exposed as described in detail previously [20] . Catheters were inserted into either portal vein or femoral vein. Either exendin-4 or saline was infused (2 ml/h for 15 min) into the catheter. Rats were thus divided into five groups with reference to the different dosages and routes of infusion: (i) saline in the portal vein, (ii) exendin-4 (5 μg/kg of bw) in the portal vein, (iii) exendin-4 (10 μg/kg of bw) in the portal vein, (iv) saline in the femoral vein, (v) exendin-4 (10 μg/kg) in the femoral vein.
Administration of L-NAME (N G -methyl-L-arginine methyl ester) and atropine
In an attempt to address whether NO and/or the vagus nerve were involved in mediating the positive effects noted, male Wistar rats weighing 350-430 g were injected intravenously either with the NOS (NO synthase) blocker l-NAME (25 mg/kg of bw; Sigma) or atropine (0.5 mg/kg of bw; Sigma) 10 min prior to the injection of exendin-4 (5 μg/kg) into the jugular vein [17] . At 5 min after the injection of exendin-4, 1 ml of 30 % (w/v) glucose was injected into the same vein. After another 5 min (20 min after the first intravenous injection), blood flow was measured using the microsphere technique described below.
Blood flow measurement
Whole PBF (pancreatic blood flow) and IBF were measured with a non-radioactive microsphere technique, as described previously in detail [21] . Briefly, 5 min after the injection of either 1 ml of saline or 30 % glucose, (1.5-2.0)×10 5 non-radioactive microspheres (IMT; Stason Labs), with a mean diameter of 10 μm, were injected within 10 s via the carotid catheter. Starting 5 s before the microsphere injection, and continuing for 60 s, an arterial blood sample (the reference sample) was collected from the catheter in the femoral artery into a preweighed tube. The exact withdrawal rate was then determined in each animal by weighing the sample. After securing the reference sample, another arterial blood sample was drawn for measurement of blood glucose and serum insulin concentrations. The animals were killed immediately afterwards. Pancreas and adrenal glands, as well as samples from left kidney (including both cortex and medulla), were taken out, blotted and weighed. The microsphere contents in these organs were determined separately. The tissue samples were then treated with a freeze-thawing technique to visualize the microspheres as described previously [22] , which was achieved by applying a microscope (Zeiss MB6; Leica) equipped with both bright and dark field illumination.
The number of microspheres in the islet and exocrine parenchyma was counted blindly. The microsphere content of each of the arterial reference samples was determined by transferring the samples to glass microfibre filters and counting the microspheres under a stereo microscope.
The blood flow values were calculated according to the equation:
where Q org is the organ blood flow (ml/min), Q ref is the withdrawal rate of the reference sample (ml/min), N org is the number of microspheres present in the organ and N ref is the number of microspheres in the reference sample. The microsphere contents of the adrenal glands were used as a control to confirm an even distribution of the microspheres in the arterial circulation. A difference of <10 % in blood flow values between the adrenal glands was used to confirm adequate mixing of the spheres in the circulation.
Measurement of blood glucose and serum insulin concentrations
Blood glucose concentrations were measured with a glucose meter (Ascensia Contour; Bayer HealthCare) and serum insulin concentrations with ELISA kits (rat insulin ELISA; Mercodia).
Statistical analysis
All values are given as means + − S.E.M. For comparisons of means among more than two groups, one-way ANOVA followed by two-tail Bonferroni post-hoc tests were adopted. For statistical comparisons between the subgroups within each group, an unpaired Student's t test was used. P < 0.05 was considered to be statistically significant.
RESULTS
GLP-1 and exendin-4 improve glucose tolerance in normoglycaemic rats
An intravenous bolus injection of GLP-1-(7-36), exendin-4 and C-peptide markedly decreased the rise in blood glucose concentration at 30 min after an intraperitoneal glucose load ( Figure 1A ). At 60 min after the glucose load, only GLP-1-(7-36) and exendin-4 still showed glucose-lowering effects, and no marked difference in glycaemia was observed between rats treated with C-peptide and saline ( Figure 1A ). Glucose tolerance was significantly improved in rats treated with GLP-1-(7-36) and exendin-4, but not with C-peptide ( Figure 1B) . At 10 min after the glucose load, only GLP-1-treated rats showed markedly elevated serum insulin concentrations;
Figure 1 Glycaemia and serum insulin concentrations during IPGTT
Immediately ater the intraperitoneal glucose bolus (30 % w/v, 2 g of glucose/kg of bw), 1 ml of saline, GLP-1-(7-36) (50 μg/kg of bw, exendin-4 (5 μg/kg of bw) or C-peptide (75 nmol/kg of bw) were injected intravenously into anaesthetized adult male Wistar rats. All substances were dissolved in 1 ml of 0.9 % saline. Blood samples were drawn from the tail vein immediately before and 10, 30, 60 and 120 min after glucose administration. Blood glucose concentrations (A) were measured by a glucose meter. Changes in the glucose response are expressed as the area under the curve (AUC) integrated over 120 min (B). Serum insulin concentrations (C) were measured by ELISA kits. Changes in the insulin response are expressed as the AUC integrated over 120 min (D). Values represent means + − S.E.M. for 5-6 animals.
* P < 0.05, * * P < 0.01 and * * * P < 0.001 compared with controls, as determined using an unpaired Student's t test.
however, at 30 and 60 min after the glucose load, serum insulin concentrations were substantially enhanced in all the groups when compared with saline-treated controls ( Figure 1C ). In vivo insulin secretion induced by the intraperitoneal glucose load was significantly increased in groups treated with GLP-1-(7-36), exendin-4 and Cpeptide ( Figure 1D ).
GLP-1 and exendin-4 decrease islet hyperperfusion in hyperglycaemic rats
An intravenous bolus injection of 1 ml 30 % glucose markedly increased both PBF and IBF when compared with saline-treated controls ( Figure 2 ). Also, fIBF (fractional IBF; the fraction of whole PBF through the islets) was significantly increased ( Figure 2C ). In saline-treated subgroups, no significant differences were observed in either PBF, IBF or fIBF, between pretreatment with either saline, GLP-1-(7-36) or exendin-4, while administration of C-peptide markedly increased both IBF and fIBF ( Figures 2B and 2C ). In the glucosetreated subgroups, neither GLP-1-(7-36) nor exendin-4 or C-peptide affected the glucose-induced increase in PBF and IBF ( Figure 2) . However, the difference in fIBF between saline-treated and glucose-treated subgroups was not statistically significant in groups pre-treated with exendin-4 and GLP-1-(7-36). Intervention with exendin-4 markedly decreased the glucose induced fIBF increase (P < 0.05) when compared with corresponding controls. A slight increase in fIBF was observed in salinetreated, but not glucose-treated, rats given C-peptide ( Figure 2C ).
Exendin-4 decreases glycaemia without further enhancing serum insulin concentrations
After the surgical procedures, no significant differences between any of the groups were observed in terms of MAP (mean arterial pressure), glycaemia or body temperature (results not shown). No significant differences of MAP were observed after intravenous injection of the tested substances (Table 1 ). In the salinetreated rats, exendin-4 induced a slight but statistically significant decrease of glycaemia which was within the physiological range, while no significant changes in blood glucose concentrations were observed in groups given GLP-1-(7-36) or C-peptide (Table 1) . Also, no significant changes in serum insulin concentrations were observed in saline-treated rats. In the glucose-treated animals, neither GLP-1-(7-36) nor C-peptide affected glycaemia, while exendin-4 again significantly decreased the blood glucose concentrations ( Table 1) . As expected, serum insulin concentrations were markedly elevated in all glucose-treated rats compared with saline-treated animals. GLP-1-(7-36), but not exendin-4, induced a 
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Figure 2 Changes in pancreatic islet microcirculation induced by GLP-1, exendin-4 and C-peptide with and without glucose administration
Total PBF (A), pancreatic IBF (B) and fIBF (C) in adult male Wistar rats were measured using a non-radioactive microsphere technique. Ten minutes before blood flow measurements, the rats were given an intravenous injection of 0.2 ml of saline (control), GLP-1 (7-36) (50 μg/kg of bw), exendin-4 (5 μg/kg of bw) or C-peptide (75 nmol/kg of bw), which were dissolved in 0.2 ml of saline. After 5 min (i.e. 5 min before the blood flow measurements), an intravenous injection of 1 ml of saline (saline-treated) or 30 % glucose (glucose-treated) solution was given. Values represent means + − S.E.M. for 6-7 animals. * P < 0.05, * * P < 0.01 and * * * P < 0.001 compared with the saline-treated groups; P < 0.05 compared with the saline-treated controls; # P < 0.05 compared with the glucose-treated controls. further marked augmentation when compared with glucose-treated controls (Table 1) .
Exendin-4, but not GLP-1, prevents the glucose-induced increase in KBF (kidney blood flow)
No significant differences in adrenal blood flow were observed between saline-treated and glucose-treated subgroups, irrespective of the pre-treatment (Table 1) . Glucose injection induced a significant increase in KBF. Administration of GLP-1-(7-36) significantly increased basal KBF, but did not affect KBF stimulated by glucose. Conversely, exendin-4 had no effect on basal KBF, whereas it prevented the increase in KBF induced by glucose. C-peptide elevated basal KBF significantly, but had no effect on glucose-stimulated KBF (Table 1) .
Exendin-4 decreases glycaemia and splanchnic blood flow by systemic, but not portal, administration in normoglycaemic rats
Infusion of the GLP-1R agonist exendin-4 directly into the portal vein, known to contain a GLP-1-regulated glucose sensor [19] , affected neither glycaemia nor splanchnic blood flow, regardless of the dosages (Table 2) . In contrast, when exendin-4 was infused into the femoral vein at the dosage of 10 μg/kg of bw, a significant decrease in blood glucose concentration, IBF, duodenal blood flow and KBF was observed ( Table 2) .
Glycaemic and vascular effects of the NOS inhibitor L-NAME and atropine in hyperglycaemic rats
In a separate series of experiments (Table 3 and Figure 3 ), attempting to address whether NO and/or the vagus nerve were involved in mediating the positive effects noted, 1 ml of 30 % glucose was injected 5 min before blood flow measurements. MAPs before the injection of the tested substances were similar in all the groups (results not shown). At the time of blood flow measurement, MAP was significantly higher in the l-NAME-pretreated group than in the other three groups. The NOS inhibitor l-NAME did not prevent the decreased IBF, PBF and post-load glycaemia evoked by exendin-4, but rather tended to further decrease IBF and KBF and increase basal glycaemia (Table 3 and Figure 3 ). Blocking the vagus nerve by atropine enhanced IBF and pancreatic IBF, leaving the proportion of IBF out of total PBF unaltered and further decreased postload glycaemia and KBF and increased basal glycaemia (Table 3 and Figure 3 ).
DISCUSSION
We show in the present study that rat islet microcirculation and glycaemia can be regulated by native GLP-1, by its stabile mimetic exendin-4 and by C-peptide. Our results confirm previous findings [21] [22] [23] [24] that glucose administration acutely and markedly stimulates both PBF and IBF, and induces a re-distribution of PBF diverting it into the islets, such that the fraction IBF out of PBF (i.e. fIBF) is augmented by glucose. This is mediated
Figure 3 Glycaemic and vascular effects of atropine and NO synthase inhibitor L-NAME in hyperglycaemic rats
In an attempt to address whether NO and/or the vagus nerve were involved in mediating the effects noted, either atropine (0.5 mg/kg of bw) or L-NAME (25 mg/kg of bw) was injected intravenously 10 min before the administration of exendin-4 (5 μg/kg of bw) and 5 min before the bolus intravenous injection of 1 ml of 30 % glucose. PBF and IBF were measured using a non-radioactive microsphere technique. Values represent means + − S.E.M. for 7 or 10 animals. One-way ANOVA followed by Bonferroni's post-hoc test was used for the statistical analysis.
* P < 0.05 and * * * P < 0.001 compared with hyperglycaemic controls; # P < 0.05 compared with the exendin-4-treated group. P < 0.05 compared with the the L-NAME-pre-treated group.
by complicated interactions between the nervous system and metabolically induced signals [18] . In contrast with a previous report [4] , intravenous administration of GLP-1 did not affect basal islet microcirculation acutely in our male Wistar rats. Although a tendency towards increased basal IBF and decreased stimulated IBF was observed, no Table 3 Glycaemic and blood pressure effects of atropine and NO synthase inhibitor L-NAME in hyperglycaemic rats See Materials and methods section for details. Values are means + − S.E.M. For statistical analyses of differences between groups, one-way ANOVA followed by Bonerroni's post-hoc test was adopted.
* P < 0.01 and * * P < 0.001 compared with the control group; # P < 0.05, ## P < 0.01 and ### P < 0.001 comapred with the exendin-4 group; P < 0.05 compared with the L-NAME + exendin-4 group. i.v., intravenous.
Parameter
Control (n = 7) Exendin-4 (n = 7) L-NAME + exendin-4 (n = 10) Atropine + exendin-4 (n = statistical significance was attained. Possible reasons for the discrepancy might involve differences in the strain and gender of the experimental animals, and the time point chosen to measure the blood flow. We chose 5 min after the glucose challenge as the cut-off point because previous studies indicate that a maximal IBF response was obtained by that time point [24] , as a result of the combination of vagal nerve input and adenosine [18] . Notably, we found that the redistribution of blood flow (fIBF) induced by glucose was prevented by GLP-1, which is in accordance with previous findings [4] . Since islet hyperperfusion is a noticeable feature in many animal models of diabetes, it can be that chronically elevated islet blood perfusion resulting in increased capillary pressure might contribute to islet dysfunction [2, 4] . Thus, the blocking effect of GLP-1 on glucose-induced increases in IBF may serve to ameliorate hemodynamic stress and thus to protect islet function. In our experimental setting, a bolus injection of exendin-4 induced similar changes as GLP-1 in pancreatic microcirculation, suggesting that the vasoactive effect of GLP-1 and exendin-4 on pancreatic vasculature might be conveyed via the same pathway: the GLP-1 receptor on the endothelial cells. It has been shown that GLP-1 relaxes pulmonary artery rings in an endothelium-dependent manner [25] and that endothelial cells regulate vascular tone and vascular reactivity with the release of a variety of contracting and relaxing factors [26] . We thus propose that the regulation of pancreatic microcirculation by acute intravenous injection of GLP-1R agonists is, at least partly, mediated by endothelium-dependent mechanisms, even though this awaits further experimental verification. To address whether NO, produced in the endothelium, is involved in these microcirculatory and metabolic effects, we used the NOS inhibitor l-NAME. However, this did not prevent the decreased IBF, PBF and postload glycaemia evoked by exendin-4, but rather tended to further decrease IBF and KBF and increase basal glycaemia. This suggests that NO does not mediate in the lowering effects of GLP-1R activation on islet microcirculation and glycaemia, but rather that basal NO is required to maintain normal islet microcirculation and glycaemia. Addressing the involvement of the vagus nerve in the effects of GLP-1R activation on islet microcirculation and glycaemia, its inhibition also prevented the decrease in IBF and whole PBF and further decreased post-load glycaemia evoked by exendin-4, indicating that the vagus nerve mediates the decreased IBF, but not glycaemia, elicited by GLP-1R activation.
When exendin-4 was infused directly into the portal vein at different doses, no changes of glycaemia, PBF, IBF and duodenal blood flow was observed. The rationale for this route of administration is that there is evidence of a GLP-1-sensitive glucose sensor in the portal vein regulating glycaemia in rodents [19] . This indicates that activating the portal vein glucose sensor by GLP-1R agonism does not affect glycaemia in this model. In contrast, when infused systemically into the femoral vein, exendin-4 decreased blood glucose concentrations, IBF and KBF as well as duodenal blood flow. Our results, together with the results by others showing that exendin-4 reduced mesenteric vascular conductance [11] , suggest that the GLP-1R agonist is not involved in the regulation of splanchnic blood flow during postabsorptive conditions.
In our studies, injection of GLP-1 significantly augmented basal KBF and further elevated KBF after the glucose load, while exendin-4 did not affect basal KBF and prevented the increase of KBF induced by glucose administration. These results suggest that the vasoactive effect of exendin-4 on splanchnic blood flow is different from that of GLP-1. In addition, we observed a transient 10 % reduction in MAP right after the injection of exendin-4 that returned to baseline within 5 min. On the other hand, after the injection of GLP-1, MAP tended to increase by approximately 10-15 mmHg, which also reverted to baseline (results not shown). There are several potential explanations for this discrepancy between GLP-1 and exendin-4 actions. First, it has been suggested that exendin-4 exerts cardiovascular effects through both GLP-1 receptor-dependent and -independent mechanisms [27, 28] . Secondly, based on evidence [28, 29] that the cardioprotective effects differ between exendin-4 and GLP-1-(9-36) amide (a degradation metabolite of native GLP-1) it may be that different receptor entities mediate the different effects of the two peptides.
A bolus intravenous injection of C-peptide significantly increased basal pancreatic IBF, fIBF and KBF, while the same tendency, albeit not statistically significant, was seen for PBF. On the other hand, no significant differences in organ blood flow were observed under hyperglycaemic conditions in response to C-peptide. These results differ from previous in vivo studies done on normal subjects and animals when exogenous C-peptide showed no vasoactive effects. C-peptide has been shown to exert several beneficial effects against neuropathy, nephropathy and myocardial dysfunction in Type 1 diabetic subjects and animal models [14, 30] . When applied to healthy subjects, C-peptide did not affect forearm blood flow [14] . In in vitro studies, perfusion with C-peptide did not affect isolated islet arterioles from normoglycaemic mice [15] . The discrepancy might in part be explained by the fact that the C-peptide concentrations reached in the present study were most likely higher than the physiological interval of 0.5-3.0 nM.
Specific binding of C-peptide to cell membrane binding sites has been demonstrated for various cell types, and this leads to an up-regulation of eNOS (endothelial NOS) transcription and activity [31] , thereby augmenting NO production. The heightened blood flow observed in islet and kidney induced by C-peptide is entirely consistent with such an effect on NO production in the vascular endothelium, dilating the afferent vessels and thereby enhancing blood flow to these organs [32] . In conclusion, we found that GLP-1, exendin-4 and C-peptide stimulated insulin secretion in a glucose-dependent manner and significantly decreased glycaemia after glucose administration. Both GLP-1 and exendin-4 prevented the glucose-induced blood flow redistribution into islets, which may serve to protect islet function against chronic haemodynamic stress evoked by hyperglycaemia. C-peptide increased basal IBF and fIBF, but did not affect islet microcirculation after glucose administration. The vascular modulatory effect on pancreatic islet microcirculation might be one of the mechanisms behind the anti-diabetic actions of GLP-1 and its long acting analogue exendin-4, as well as that of C-peptide.
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